- Home
- REBN vs CYCN Comparison
REBN vs CYCN Comparison
Compare REBN & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- CYCN
- Stock Information
- Founded
- REBN 2015
- CYCN 2018
- Country
- REBN United States
- CYCN United States
- Employees
- REBN N/A
- CYCN N/A
- Industry
- REBN Restaurants
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- CYCN Health Care
- Exchange
- REBN Nasdaq
- CYCN Nasdaq
- Market Cap
- REBN 13.5M
- CYCN 6.5M
- IPO Year
- REBN 2022
- CYCN N/A
- Fundamental
- Price
- REBN $2.50
- CYCN $3.19
- Analyst Decision
- REBN
- CYCN
- Analyst Count
- REBN 0
- CYCN 0
- Target Price
- REBN N/A
- CYCN N/A
- AVG Volume (30 Days)
- REBN 48.0K
- CYCN 18.5K
- Earning Date
- REBN 05-20-2025
- CYCN 08-06-2025
- Dividend Yield
- REBN N/A
- CYCN N/A
- EPS Growth
- REBN N/A
- CYCN N/A
- EPS
- REBN N/A
- CYCN N/A
- Revenue
- REBN $6,103,732.00
- CYCN $2,081,000.00
- Revenue This Year
- REBN $335.98
- CYCN N/A
- Revenue Next Year
- REBN N/A
- CYCN N/A
- P/E Ratio
- REBN N/A
- CYCN N/A
- Revenue Growth
- REBN 3.38
- CYCN N/A
- 52 Week Low
- REBN $1.03
- CYCN $1.27
- 52 Week High
- REBN $8.80
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- REBN 40.34
- CYCN 51.28
- Support Level
- REBN $2.35
- CYCN $2.94
- Resistance Level
- REBN $2.68
- CYCN $3.31
- Average True Range (ATR)
- REBN 0.15
- CYCN 0.24
- MACD
- REBN 0.01
- CYCN 0.00
- Stochastic Oscillator
- REBN 25.49
- CYCN 65.75
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.